Jacob Glanville
Jacob Glanville is the CEO and President of Centivax, a biotechnology company based in San Francisco. He is known for his work in the field of immunology and infectious diseases, focusing on the development of vaccines and therapeutic strategies. Glanville recently commented on the significance of Zoetis’ bird flu vaccine, emphasizing its potential to control avian influenza outbreaks and protect the agricultural economy, highlighting the urgent need for effective vaccination strategies in livestock.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 6.00 | 0.02% | +0% | 331,002,651 | 73,458 | $21,000,000 | 4,660$ |
| Totals | 1 | 331,002,651 | 73,458 | $21,000,000 | 4,660$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Dr. Jacob Glanville, CEO of Centivax, a San Francisco biotechnology company, echoed that the study has not yet undergone peer review.
6
United States:
Jacob Glanville, CEO and president of biotechnology company Centivax, noted that Zoetis’ bird flu vaccine is intended for veterinary use on bird flocks.
8